Baker Bros. Advisors Adds $857K in Disc Medicine, Inc. ($IRON)
Key Points
- Baker Bros. Advisors changed its Disc Medicine, Inc. ($IRON) stake by 3.7% last quarter, boosting to 349,657 shares worth $23.77 million.
- Wall Street's consensus rating on $IRON is Strong Buy and an average price target of $101.09.
- $IRON last traded around $67.99.
Baker Bros. Advisors increased its position in Disc Medicine, Inc. ($IRON) by 3.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 349,657 shares of Disc Medicine, Inc. after buying 12,607 shares during the quarter. Baker Bros. Advisors's holdings in Disc Medicine, Inc. were worth $23.77 million as of its most recent filing.
Disc Medicine, Inc. ($IRON) Stock
Disc Medicine, Inc. Earnings
Analysts Set New Price Targets
About Disc Medicine, Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.